Baliopharm AG is a biotechnology company developing antibody therapeutics for chronic liver diseases, immune-mediated inflammatory diseases and oncology. Its portfolio includes monoclonal antibodies and antibody-derived formats such as monovalent and bispecific constructs designed for targeted selectivity.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
✓ Offered
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of monoclonal antibodies and antibody-based therapeutics for chronic liver diseases, immune-mediated inflammatory diseases, and cancer.
Co-development and licensing
Assets for co-development and licensing, including collaboration with industry partners to further develop the lead compounds Atrosab, Atrosimab and Novotarg.
Knowledge
No knowledge articles yet
Once Baliopharm AG has claimed this profile, we'll publish editorial articles and case studies here together.